NAVLE Musculoskeletal

Canine Degenerative Joint Disease Study Guide

📅 March 28, 2026 ⏱ 25 min read 👁 10 views

Overview and Clinical Importance

Degenerative joint disease (DJD), also known as osteoarthritis (OA), is a chronic, progressive condition of synovial joints characterized by articular cartilage degeneration, periarticular osteophyte formation, subchondral bone changes, and synovial inflammation. It affects approximately 20% of dogs over one year of age. In dogs, OA is most commonly secondary to developmental orthopedic diseases (hip/elbow dysplasia, OCD), traumatic injuries (CCL rupture), or joint instability.

Classification	Description and Causes
Primary (Idiopathic)	Naturally occurring degeneration without identifiable cause; less common in dogs compared to humans
Secondary OA	Developmental: Hip dysplasia, elbow dysplasia, OCD, patellar luxation Traumatic: CCL rupture, fractures, luxations Inflammatory: Immune-mediated, septic arthritis

Etiology and Risk Factors

Classification of Osteoarthritis

Breed Predispositions

High-YieldFor NAVLE, remember the 'Big Three' breeds for hip dysplasia: Labrador Retriever, German Shepherd, and Golden Retriever. For elbow dysplasia, add Rottweiler and Bernese Mountain Dog. Slender breeds like Greyhounds and Whippets have the lowest hip dysplasia incidence.

Modifiable and Non-Modifiable Risk Factors

NAVLE TipDiet restriction studies demonstrate that maintaining lean body condition can delay hip OA onset by up to 3 years and reduce need for pharmaceutical intervention. This is a frequently tested concept.

Breed	Primary Predisposition	OA Location
Labrador Retriever	Hip dysplasia, elbow dysplasia, CCL disease	Hip, elbow, stifle
German Shepherd	Hip dysplasia, elbow dysplasia	Hip, elbow, lumbosacral spine
Golden Retriever	Hip dysplasia, elbow dysplasia, CCL disease	Hip, elbow, stifle
Rottweiler	Elbow dysplasia, OCD	Elbow, shoulder, stifle
Bernese Mountain Dog	Elbow dysplasia, hip dysplasia	Elbow, hip
Yorkshire Terrier	Medial patellar luxation, Legg-Calve-Perthes	Stifle, hip

Pathophysiology

Normal Joint Structure

A healthy synovial joint consists of articular cartilage (hyaline, 2-4 mm thick, avascular/aneural), extracellular matrix (Type II collagen, proteoglycans/aggrecan, 60-80% water), synovial membrane (produces synovial fluid), and subchondral bone (provides structural support).

Pathogenesis of Cartilage Degeneration

OA is a disease of the entire joint organ. The pathogenesis involves mechanical and biological factors in a progressive cascade.

Stage 1: Initiation

Abnormal mechanical loading causes microtrauma to articular cartilage. Chondrocytes respond by increasing production of matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS), initiating ECM degradation.

Stage 2: Inflammation

Cartilage degradation products activate synovial macrophages, triggering release of pro-inflammatory cytokines: Interleukin-1 (IL-1) and Tumor Necrosis Factor-alpha (TNF-?). These upregulate MMP production, creating a destructive positive feedback loop. Synovitis develops with joint effusion.

Stage 3: Progressive Degeneration

Continued cartilage loss exposes subchondral bone. Pain develops through: subchondral bone exposure, capsular distension, synovitis, and periosteal stretching. Nerve Growth Factor (NGF) levels increase, sensitizing peripheral nociceptors.

Stage 4: Remodeling

Osteophytes form at joint margins. Subchondral sclerosis develops. Enthesophytes form at ligament insertions. Joint capsule becomes fibrotic.

Memory Aid - OA Pathophysiology "DISC": D = Degradation of cartilage matrix (MMPs, aggrecanases) | I = Inflammation (IL-1, TNF-?, synovitis) | S = Subchondral bone changes (sclerosis, exposure) | C = Compensatory remodeling (osteophytes, enthesophytes)

Non-Modifiable	Modifiable
Breed/Genetics: Heritable developmental diseases Age: Cartilage composition changes, reduced repair Previous Injury: Fractures, luxations, ligament rupture Conformation: Joint angles, limb alignment	Obesity: Increased load, pro-inflammatory adipokines Diet: Rapid growth in large breeds, nutritional imbalances Exercise: Excessive high-impact during development Environment: Slippery flooring during growth Early Neuter: Associated with increased developmental disease

Clinical Presentation

History and Owner-Reported Signs

Physical Examination Findings

Gait Evaluation

Observe at walk and trot on non-slip surface. Note stride length, weight-bearing, head bob (thoracic limb lameness). Evaluate rising from sitting/lying. Assess symmetry of movement.

Joint Examination

Joint-Specific Tests

Hip: Ortolani maneuver (detects hip laxity in young dogs), pain on hip extension, decreased abduction.

Stifle: Cranial drawer test, tibial thrust (detect CCL rupture), medial buttress, joint effusion, pain on flexion/extension.

Elbow: Pain on flexion/extension, decreased ROM, effusion between lateral epicondyle, olecranon, and radial head.

High-YieldClassic hip OA presentation: large-breed dog with difficulty rising, bunny-hopping gait, reluctance to climb stairs, hindquarter muscle atrophy, and pain on hip extension. Ortolani test is positive in young dogs with hip laxity but may become negative as fibrosis develops.

Category	Clinical Signs
Mobility Changes	Difficulty rising after rest ("morning stiffness"), reluctance to climb stairs/jump, shortened stride, limping, bunny-hopping gait (bilateral hindlimb)
Activity Changes	Exercise intolerance, reluctance to play, lagging behind on walks, decreased activity level
Behavioral Changes	Increased irritability when touched, vocalization, increased sleeping, posture changes, excessive licking at joints

Diagnosis

Radiographic Evaluation

Radiography is the gold standard for OA diagnosis. Orthogonal views (minimum two perpendicular projections) are essential.

Radiographic Signs of OA

Exam Focus: Radiographic changes do NOT always correlate with clinical severity. Dogs may have significant radiographic OA with minimal clinical signs, or severe pain with mild radiographic changes. Treatment decisions should be based on clinical signs, not radiographs alone.

COAST Staging System

The Canine OsteoArthritis Staging Tool (COAST) provides standardized OA assessment using a 0-4 scale incorporating owner assessment, veterinary examination, and radiographs.

Finding	Clinical Significance
Joint effusion	Synovitis, increased synovial fluid. Palpable as fluctuant swelling.
Pain on manipulation	Capsular distension, synovitis, subchondral bone involvement.
Crepitus	Palpable/audible grinding during ROM. Indicates cartilage loss, bone-on-bone contact.
Decreased ROM	Joint capsule fibrosis, osteophyte impingement, muscle contracture.
Muscle atrophy	Disuse atrophy from chronic lameness. Compare bilaterally.
Periarticular thickening	Osteophyte formation, capsular fibrosis. Firm, non-painful swelling.

Treatment and Management

OA requires a multimodal approach addressing pain, inflammation, joint health, and underlying causes. Goals: control pain, slow progression, maintain mobility, optimize quality of life.

Non-Pharmaceutical Management (Foundational for ALL Stages)

Weight Management

The single most important intervention. Excess weight increases mechanical load and adipose tissue produces pro-inflammatory adipokines. Target BCS 4-5/9. Studies show lean body condition can delay OA onset by up to 3 years.

Exercise Modification

Regular, controlled, low-impact exercise (leash walks, swimming). Avoid high-impact activities (jumping, ball chasing). Maintain consistent activity - avoid "weekend warrior" syndrome.

Environmental Modifications

Orthopedic bedding, ramps instead of stairs, non-slip rugs on slippery floors, elevated food/water bowls, keep nails trimmed.

Pharmaceutical Management

NSAIDs - Cornerstone of OA Pain Management

High-YieldNSAIDs should NOT be combined with each other or with corticosteroids (increased GI ulceration risk). A 5-7 day washout period is recommended when switching NSAIDs or from corticosteroids to NSAIDs.

Bedinvetmab (Librela) - Anti-NGF Monoclonal Antibody

Adjunctive Analgesics

Disease-Modifying Agents and Nutraceuticals

PSGAG (Adequan): 4.4 mg/kg IM twice weekly x 4 weeks. Proposed chondroprotective effects.

Omega-3 Fatty Acids: Best nutraceutical evidence. Anti-inflammatory effects through prostaglandin modulation.

Glucosamine/Chondroitin: Limited evidence in dogs. Safe. May take 4-6 weeks for effect.

Physical Rehabilitation

Hydrotherapy (underwater treadmill, swimming), therapeutic exercises (leash walks, sit-to-stand, cavaletti), manual therapies (passive ROM, massage), modalities (laser therapy, therapeutic ultrasound, TENS).

Surgical Management

NAVLE TipRemember ABCDE of OA management: Analgesia, Bodyweight management, Controlled exercise, Disease-modifying agents, Environmental modifications.

Finding	Description
Osteophytes	Bony projections at joint margins. Most reliable OA indicator.
Enthesophytes	Mineralization at ligament/tendon insertions.
Subchondral sclerosis	Increased bone opacity beneath articular surface.
Joint space narrowing	Indicates cartilage loss. Less reliable sign.
Soft tissue swelling	Joint effusion, synovial thickening, capsular distension.
Joint mice	Mineralized intra-articular fragments.

Prognosis

OA is progressive and incurable, but prognosis for quality of life is generally good to fair with appropriate multimodal management. Factors affecting prognosis: number/severity of affected joints, underlying cause, patient age/size, owner compliance, concurrent diseases. Early intervention and weight management significantly slow progression.

Stage	Description	Clinical Findings
0	Clinically normal, no risk factors	No clinical signs, no predisposing conditions
1	Clinically normal with risk factors	No current signs but has predisposing factors
2	Mild OA	Mild, intermittent signs. Responds to basic management.
3	Moderate OA	Consistent signs affecting daily activities. Requires multimodal management.
4	Severe OA	Severely affected mobility. May require aggressive therapy or surgery.

Drug	Dose	Selectivity	Notes
Carprofen	2.2 mg/kg PO q12h or 4.4 mg/kg q24h	COX-2 preferential	First canine NSAID (1996). Well-established.
Meloxicam	0.1 mg/kg PO q24h (load: 0.2 mg/kg)	COX-2 preferential	Liquid formulation. Once-daily dosing.
Firocoxib	5 mg/kg PO q24h	COX-2 selective	Highly selective. Lower GI risk theory.
Grapiprant	2 mg/kg PO q24h	EP4 antagonist	Novel mechanism. Blocks PGE2 receptor.

Parameter	Details
Mechanism	Binds/neutralizes canine NGF, blocking NGF-TrkA signaling
Dose	0.5-1.0 mg/kg SC once monthly
Advantages	Novel mechanism, monthly dosing (compliance), no COX inhibition
Considerations	Reported neurologic adverse events (ataxia, seizures) - FDA monitoring. Long-term NSAID concurrent use not well-studied.

Drug	Dose	Notes
Gabapentin	5-10 mg/kg PO q8-12h	Calcium channel modulator. Neuropathic pain. Sedation common.
Amantadine	3-5 mg/kg PO q24h	NMDA antagonist. Reduces central sensitization. Add-on for refractory pain.

Procedure	Indication
TPLO/TTA/Lateral Suture	CCL rupture - stabilize stifle
Total Hip Replacement	Severe hip OA. Eliminates bone-on-bone. Excellent outcomes.
FHO	Salvage for hip OA when THR not feasible. Best for dogs less than 20 kg.
Arthrodesis	Joint fusion for end-stage OA (carpus, tarsus).

Practice NAVLE Questions

Test your knowledge with 10,000+ exam-style questions, detailed explanations, and timed exams.

Start Your Free Trial →